Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Share-based Compensation for 9 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 4.49% to $24.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $99.6 million through Dec 2025, down 3.15% year-over-year, with the annual reading at $99.6 million for FY2025, 3.15% down from the prior year.
  • Share-based Compensation for Q4 2025 was $24.0 million at Denali Therapeutics, down from $25.1 million in the prior quarter.
  • The five-year high for Share-based Compensation was $28.1 million in Q1 2023, with the low at $21.0 million in Q3 2021.
  • Average Share-based Compensation over 5 years is $24.8 million, with a median of $25.1 million recorded in 2024.
  • The sharpest move saw Share-based Compensation skyrocketed 94.97% in 2021, then dropped 9.63% in 2025.
  • Over 5 years, Share-based Compensation stood at $22.1 million in 2021, then increased by 14.05% to $25.2 million in 2022, then grew by 3.18% to $26.0 million in 2023, then decreased by 3.5% to $25.1 million in 2024, then decreased by 4.49% to $24.0 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $24.0 million, $25.1 million, and $25.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.